|
1
|
Bjoraker JA, Ryu JH, Edwin MK, Myers JL,
Tazelaar HD, Schroeder DR and Offord KP: Prognostic significance of
histopathologic subsets in idiopathic pulmonary fibrosis. Am J
Respir Crit Care Med. 157:199–203. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nicholson AG, Colby TV, du Bois RM,
Hansell DM and Wells AU: The prognostic significance of the
histologic pattern of interstitial pneumonia in patients presenting
with the clinical entity of cryptogenic fibrosing alveolitis. Am J
Respir Crit Care Med. 162:2213–2217. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Daniil ZD, Gilchrist FC, Nicholson AG,
Hansell DM, Harris J, Colby TV and du Bois RM: A histologic pattern
of nonspecific interstitial pneumonia is associated with a better
prognosis than usual interstitial pneumonia in patients with
cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med.
160:899–905. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Douglas WW, Ryu JH, Swensen SJ, Offord KP,
Schroeder DR, Caron GM and DeRemee RA: Colchicine versus prednisone
in the treatment of idiopathic pulmonary fibrosis. A randomized
prospective study Members of the Lung Study Group. Am J Respir Crit
Care Med. 158:220–225. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gribbin J, Hubbard RB, Le Jeune I, Smith
CJ, West J and Tata LJ: Incidence and mortality of idiopathic
pulmonary fibrosis and sarcoidosis in the UK. Thorax. 61:980–985.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Dennler S, Goumans MJ and ten Dijke P:
Transforming growth factor beta signal transduction. J Leukoc Biol.
71:731–740. 2002.PubMed/NCBI
|
|
7
|
Tojo M, Hamashima Y, Hanyu A, et al: The
ALK-5 inhibitor A-83-01 inhibits Smad signaling and
epithelial-to-mesenchymal transition by transforming growth
factor-beta. Cancer Sci. 96:791–800. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mori Y, Ishida W, Bhattacharyya S, Li Y,
Platanias LC and Varga J: Selective inhibition of activin
receptor-like kinase 5 signaling blocks profibrotic transforming
growth factor beta responses in skin fibroblasts. Arthritis Rheum.
50:4008–4021. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ishida W, Mori Y, Lakos G, et al:
Intracellular TGF-beta receptor blockade abrogates Smad-dependent
fibroblast activation in vitro and in vivo. J Invest Dermatol.
126:1733–1744. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu XJ, Ruan CM, Gong XF, Li XZ, Wang HL,
Wang MW and Yin JQ: Antagonism of transforming growth factor-Beta
signaling inhibits fibrosis-related genes. Biotechnol Lett.
27:1609–1615. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Borzone G, Moreno R, Urrea R, Meneses M,
Oyarzun M and Lisboa C: Bleomycin-induced chronic lung damage does
not resemble human idiopathic pulmonary fibrosis. Am J Respir Crit
Care Med. 163:1648–1653. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hoyt DG and Lazo JS: Alterations in
pulmonary mRNA encoding procollagens, fibronectin and transforming
growth factor-beta precede bleomycin-induced pulmonary fibrosis in
mice. J Pharmacol Exp Ther. 246:765–771. 1988.PubMed/NCBI
|
|
13
|
Osborne ML, Vollmer WM, Linton KL and
Buist AS: Characteristics of patients with asthma within a large
HMO: a comparison by age and gender. Am J Respir Crit Care Med.
157:123–128. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chaudhary NI, Schnapp A and Park JE:
Pharmacologic differentiation of inflammation and fibrosis in the
rat bleomycin model. Am J Respir Crit Care Med. 173:769–776. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bouros D and Antoniou KM: Current and
future therapeutic approaches in idiopathic pulmonary fibrosis. Eur
Respir J. 26:693–702. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pfaffl MW: A new mathematical model for
relative quantification in real-time RT-PCR. Nucleic Acids Res.
29:e452001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Woessner JF Jr: The determination of
hydroxyproline in tissue and protein samples containing small
proportions of this imino acid. Arch Biochem Biophys. 93:440–447.
1961. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ashcroft T, Simpson JM and Timbrell V:
Simple method of estimating severity of pulmonary fibrosis on a
numerical scale. J Clin Pathol. 41:467–470. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Flaherty KR, Toews GB, Lynch JP, et al:
Steroids in idiopathic pulmonary fibrosis: a prospective assessment
of adverse reactions, response to therapy, and survival. Am J Med.
110:278–282. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pardo A and Selman M: Idiopathic pulmonary
fibrosis: new insights in its pathogenesis. Int J Biochem Cell
Biol. 34:1534–1538. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Selman M and Pardo A: The
epithelial/fibroblastic pathway in the pathogenesis of idiopathic
pulmonary fibrosis. Am J Respir Cell Mol Biol. 29:S93–97.
2003.PubMed/NCBI
|
|
22
|
Tomasek JJ, Gabbiani G, Hinz B, Chaponnier
C and Brown RA: Myofibroblasts and mechano-regulation of connective
tissue remodelling. Nat Rev Mol Cell Biol. 3:349–363. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gabbiani G, Ryan GB and Majne G: Presence
of modified fibroblasts in granulation tissue and their possible
role in wound contraction. Experientia. 27:549–550. 1971.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chaudhary NI, Roth GJ, Hilberg F, et al:
Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis.
Eur Respir J. 29:976–985. 2007. View Article : Google Scholar : PubMed/NCBI
|
